TCGA-PE-A5DD-01A-12R-A27Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 65
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.330
- MYOGENESIS+0.300
- NOTCH_SIGNALING+0.270
- WNT_BETA_CATENIN_SIGNALING+0.260
- HEDGEHOG_SIGNALING+0.230
- COAGULATION+0.130
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.070
- KRAS_SIGNALING_DN+0.070
- P53_PATHWAY+0.050
- APICAL_JUNCTION+0.040
Top 10 suppressed
- MYC_TARGETS_V1-0.510
- PROTEIN_SECRETION-0.510
- MTORC1_SIGNALING-0.470
- E2F_TARGETS-0.390
- G2M_CHECKPOINT-0.380
- ANDROGEN_RESPONSE-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.290
- MITOTIC_SPINDLE-0.270
- MYC_TARGETS_V2-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.905 |
| 2 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.872 |
| 3 | MBCProject_0003_T2_RNA | — | A | 0.861 |
| 4 | SRR25617847 | — | C | 0.854 |
| 5 | 9176b038-65e3-469d-a867-d99bc732e45d | — | — | 0.844 |
| 6 | SRR1313107 | — | F | 0.834 |
| 7 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.834 |
| 8 | 12305e97-f72f-4de7-9735-4cdbecb60296 | — | — | 0.829 |
| 9 | R37 | — | — | 0.828 |
| 10 | SRR27320690 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |